RT Journal Article
T1 Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
A1 Sapena, Victor
A1 Enea, Marco
A1 Torres, Ferran
A1 Celsa, Ciro
A1 Rios, Jose
A1 Rizzo, Giacomo Emanuele Maria
A1 Nahon, Pierre
A1 Mariño, Zoe
A1 Tateishi, Ryosuke
A1 Minami, Tatsuya
A1 Sangiovanni, Angelo
A1 Forns, Xavier
A1 Toyoda, Hidenori
A1 Brillanti, Stefano
A1 Conti, Fabio
A1 Degasperi, Elisabetta
A1 Yu, Ming-Lung
A1 Tsai, Pei-Chien
A1 Jean, Kevin
A1 El Kassas, Mohamed
A1 Shousha, Hend Ibrahim
A1 Omar, Ashraf
A1 Zavaglia, Claudio
A1 Nagata, Hiroko
A1 Nakagawa, Mina
A1 Asahina, Yasuhiro
A1 Singal, Amit G
A1 Murphy, Caitlin
A1 Kohla, Mohamed
A1 Masetti, Chiara
A1 Dufour, Jean-François
A1 Merchante, Nicolas
A1 Cavalletto, Luisa
A1 Chemello, Liliana Lc
A1 Pol, Stanislas
A1 Crespo, Javier
A1 Calleja, Jose Luis
A1 Villani, Rosanna
A1 Serviddio, Gaetano
A1 Zanetto, Alberto
A1 Shalaby, Sarah
A1 Russo, Francesco Paolo
A1 Bielen, Rob
A1 Trevisani, Franco
A1 Cammà, Calogero
A1 Bruix, Jordi
A1 Cabibbo, Giuseppe
A1 Reig, Maria
K1 antiviral therapy
K1 hepatocellular carcinoma
K1 meta-analysis
AB The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.
YR 2021
FD 2021-03-19
LK http://hdl.handle.net/10668/20154
UL http://hdl.handle.net/10668/20154
LA en
DS RISalud
RD Apr 9, 2025